A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer

Colorectal cancer remains a leading source of cancer mortality worldwide. Initial response is often followed by emergent resistance that is poorly responsive to targeted therapies, reflecting currently undruggable cancer drivers such as KRAS and overall genomic complexity. Here, we report a novel ap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Adv
Main Authors: Bangi, Erdem, Ang, Celina, Smibert, Peter, Uzilov, Andrew V., Teague, Alexander G., Antipin, Yevgeniy, Chen, Rong, Hecht, Chana, Gruszczynski, Nelson, Yon, Wesley J., Malyshev, Denis, Laspina, Denise, Selkridge, Isaiah, Rainey, Hope, Moe, Aye S., Lau, Chun Yee, Taik, Patricia, Wilck, Eric, Bhardwaj, Aarti, Sung, Max, Kim, Sara, Yum, Kendra, Sebra, Robert, Donovan, Michael, Misiukiewicz, Krzysztof, Schadt, Eric E., Posner, Marshall R., Cagan, Ross L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Association for the Advancement of Science 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6531007/
https://ncbi.nlm.nih.gov/pubmed/31131321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aav6528
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados